Medthority· @Medthority · X·· 13 小时前评分70
正文 · 原文
#ESMO26
Further DeLLphi-305 results favored tarlatamab + durvalumab vs durvalumab alone in 1LM ES-SCLC
📊 Median PFS: 7.4 vs 1.9 months
📊 ORR: 26.4% vs 4.1%
CRS was predominantly low grade; no fatal CRS or ICANS events
#LungCancer #SCLC #Oncology #OncTwitter #MedEd #MedX #MedSky
92 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA3按 Presidential Symposium I 对上
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Medthority · x.com